Trastuzumab as monotherapy and in combination with a taxane for the treatment of metastatic breast cancer (to include a review of TA34).
 
Status Suspended
Process MTA
Topic area
  • Cancer
Description

A scoping workshop was held in June 2010, where potential changes to the remit of this appraisal were proposed. These proposals were put the Department of Health, who are currently in the process of considering the request to amend the remit. There are a complex set of issues to be discussed regarding the suggested changes to the remit and these need to be explored further before the Department of Health can take a decision.

Therefore, this appraisal is now suspended and we will inform you of updated arrangement for this appraisal as soon as we can.

Provisional Schedule

Consultation on draft scope by stakeholders: 24 March 2010
Information meeting with consultees: TBC
Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
2nd appraisal committee meeting: TBC

Project Team

Communications manager: Laura Gibson
Executive Lead: Andrew Dillon
Project manager: Rebecca Pye
Technical Lead: Raisa Sidhu

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance